<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3778">
  <stage>Registered</stage>
  <submitdate>16/01/2013</submitdate>
  <approvaldate>16/01/2013</approvaldate>
  <nctid>NCT01773083</nctid>
  <trial_identification>
    <studytitle>Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma</studytitle>
    <scientifictitle>Randomized Controlled Trial Investigating the Efficacy and Safety of Nebulized Heparin Versus Placebo in Burn Patients With Inhalation Trauma (Hepburn)</scientifictitle>
    <utrn />
    <trialacronym>Hepburn</trialacronym>
    <secondaryid>2012-003289-42</secondaryid>
    <secondaryid>HepBurn</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Inhalation Injury</healthcondition>
    <healthcondition>Burn Injury</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Burns</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - unfractionated heparin
Treatment: drugs - placebo

Experimental: unfractionated heparin - 25.000 IU/5 ml, will be nebulized 4 hourly (i.e. 6 times daily)

Placebo Comparator: placebo - Sterile sodium chloride (NaCl 0.9%, Pfizer), in 5 ml, will be nebulized every 4 hours (i.e. 6 times daily)


Treatment: drugs: unfractionated heparin
nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days

Treatment: drugs: placebo
Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of ventilator-free days at day 28 - The number of ventilator-free days is defined as the number of days a patient is breathing without assist of a ventilator during the first 28 days; thus, the patient must be free of mechanical ventilation for 24 hours to have one ventilator-free day; if after successful detubation the patient requires a reintubation due to a surgical procedure, this reintubation will not count as a ventilator day - however, the day(s) will be counted as ventilator day(s) if mechanical ventilation is prolonged after surgery due to respiratory insufficiency.</outcome>
      <timepoint>at day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical outcome parameters - Clinical outcome parameters will include but not be restricted to: (a) length of stay (ICU and hospital); (b) mortality (28- and 90 days); (c) mortality (ICU and hospital); (d) daily Lung Injury Score (LIS); (e) daily Oxygenation Index (OI) ; (f) daily Sequential Organ Failure Assessment (SOFA)-scores ; (g) cumulative dosages of sedatives; (h) incidence of Ventilator-associated Pneumonia (VAP); (i) total number of bronchoscopy-guided cleaning of the larger airway</outcome>
      <timepoint>daily or at day 28 and day 90</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Laboratory outcome parameters - Levels of markers of coagulation and fibrinolysis in blood and lung lavage fluid, Levels of markers of inflammation in blood and lung lavage fluid, Biomarkers of lung injury in blood and lung lavage fluid</outcome>
      <timepoint>Blood and lavage samples: on admission day and every other day for a maximum period of 14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety parameters - Safety parameters will include but not be restricted to: Occurrence of serious bleedings, any other transfusion of blood products - red cells and/or platelets and/or plasma, Confirmed Heparin induced thrombocytopenia, prolonged activated partial thromboplastin time (aPTT &gt; 150 seconds)</outcome>
      <timepoint>daily, for a maximum period of 28 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Informed consent

          -  Age &gt; 18 years

          -  Need for invasive mechanical ventilation

          -  Confirmed inhalation trauma (bronchoscopically)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  &gt; 36 hours after trauma

          -  Receiving invasive ventilation &gt; 24 hours

          -  Expected duration of mechanical ventilation &lt; 24 hours

          -  Chronic obstructive pulmonary disease GOLD stage III and IV

          -  Any history of pulmonary hemorrhage in the past 3 months

          -  Any history of significant bleeding disorder

          -  Known allergy to heparin, including heparin-induced thrombocytopenia

          -  Pregnancy or breast feeding

          -  Unlikely to survive for &gt; 72 hours

          -  Total body surface area (TBSA) &gt; 60%

          -  Witnessed or proven aspiration (i.e., confirmed by bronchoscopy)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>13</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>St Vincent's Hospital - Melbourne</hospital>
    <postcode>3065 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Oost-Vlaanderen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Vlaams-Brabant</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Noord-Holland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Zuid-Holland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Dutch Burns Foundation</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this international multi-center double-blind randomized placebo-controlled
      trial is to determine the effect of nebulized heparin, compared to placebo, on the number of
      ventilator-free days at day 28, in burn patients with confirmed inhalation trauma requiring
      mechanical ventilation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01773083</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Marcus J Schultz, MD-PhD</name>
      <address>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>